Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

NCT05954442 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

203

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer
Metastatic Breast Cancer
Mutation

Interventions

DRUG: Everolimus
DRUG: Investigator's Choice of Chemotherapy

Sponsor

Fudan University